Clinical trial
IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant…
NCT00003842 · Barrett Cancer Center, Other · Unknown status
Key facts
| NCT number | NCT00003842 |
|---|---|
| Title | IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma |
| Official title | A Phase I Study of a Recombinant Chimeric Protein Composed of Circularly Permuted IL-4 and a Mutated Form of the Pseudomonas Exotoxin Termed IL-4(38-37)-PE38KDEL (IL-4 Toxin) for the Treatment of Recurrent Malignant Astrocytoma |
| Lead sponsor | Barrett Cancer Center, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Biological, Drug, Procedure |
| Interventions | interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure |
| Enrollment | 30 |
| Start date | Mar 1, 1999 |
| First posted | Sep 14, 2004 |
| Last update posted | Dec 18, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: